Just 8-10 to 10-15 neuromuscular neurologists across six named GCC referral centres manage 70-80% of confirmed generalised myasthenia gravis, the institutional concentration this workbook sizes before a single physician is scored.
GCC generalised myasthenia gravis expertise concentrates around a small number of tertiary referral centres, not a broad regional field. An estimated 8-10 to 10-15 neuromuscular neurologists across KFSH&RC, Hamad Medical Corporation, AUH, SKMC, Cleveland Clinic Abu Dhabi, and King Fahd Medical City manage 70-80% of all confirmed GCC generalised MG. That concentration is compounded by a region-specific diagnostic confounder: an estimated 30-40% of GCC MG patients are initially misdiagnosed as thyroid myopathy, given the region's high background thyroid-disease prevalence, which routes a share of patients through endocrinology before they ever reach one of these six centres. Our KOL Universe gate (K1) starts by mapping exactly this kind of institutional concentration before any single physician is scored.
That structure changes how AXLRx tiers influence across the GCC. A neurologist practising at one of the six named tertiary centres, with AChR-antibody testing and thymectomy referral capability on site, carries materially different scientific and commercial weight than a community neurologist managing a misdiagnosed or undiagnosed case, and our Tier Classification gate (K2) scores that distinction directly, alongside efgartigimod and eculizumab access-site status. No named individual physician enters the workbook; every entry is scored and verified at the institution and community level, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity outside the small group that actually manages 70-80% of confirmed cases, which is exactly what the K1-K6 gate structure is built to prevent.
The GCC gMG referral network: six named centres and 8-10 to 10-15 neurologists managing 70-80% of confirmed cases
| Institution | Role in GCC gMG Referral Network |
|---|---|
| KFSH&RC | Tertiary reference centre; AChR-antibody testing and thymectomy capability |
| Hamad Medical Corporation | Tertiary referral and efgartigimod access site |
| AUH | Tertiary neurology referral site |
| SKMC | Tertiary neurology referral site |
| Cleveland Clinic Abu Dhabi | Refractory gMG referral site |
| King Fahd Medical City | Tertiary neuromuscular referral site |
Sources: Al-Shubaili AF, Eur Neurol 2012; KFSH&RC neurology database 2019-2023; GCC neurology society gMG working group; SFDA registration records; argenx GCC access reports 2024.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The six-centre referral network (KFSH&RC, Hamad Medical Corporation, AUH, SKMC, Cleveland Clinic Abu Dhabi, King Fahd Medical City)
- specialist-count concentration as a KOL-tiering signal
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- AChR-antibody testing, thymectomy-referral, and efgartigimod/eculizumab access-site status as weighting inputs
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live institutional-affiliation and access-site cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the six-centre GCC referral network before the rest of the workbook is built out
- Every GCC gMG specialist sized and sourced from institutional-affiliation and access-site data
- The six-centre referral network as the sizing anchor
- Universe boundaries: who counts as a specialist versus a community neurologist
- Scientific-influence scoring across access-site status and diagnostic capability
- What separates a Tier 1 specialist from a community-level referring physician
- Influence inputs: AChR-antibody testing capability, thymectomy referral role, efgartigimod/eculizumab access-site status
- Cross-checked against independent institutional data
- Readiness scoring and channel recommendations per specialist
- Sequencing implications for MSL deployment
- Territory-to-specialist coverage map across KSA, UAE, and Qatar
- Where current MSL deployment has gaps
- Multi-market reach for specialists active beyond their home country, across the wider GCC
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live institutional-affiliation and access-site data, not secondary summaries. No specialist name ships without a verification tag.
GCC myasthenia gravis KOL sources: Al-Shubaili AF, Eur Neurol 2012, the KFSH&RC neurology database (2019-2023), the GCC neurology society gMG working group, and SFDA/argenx GCC access records for efgartigimod.
- Six-centre referral network and specialist-count range (8-10 to 10-15) verified against Al-Shubaili AF, Eur Neurol 2012 and the KFSH&RC neurology database
- 70-80% case-concentration figure verified against the GCC neurology society gMG working group data
- Efgartigimod and eculizumab access-site status verified against SFDA registration records and argenx GCC access reports 2024
- Every specialist entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC generalised myasthenia gravis specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.